Northland Securities analyst Jason Wittes maintained a Buy rating on Brainsway (BWAY) today and set a price target of $15.00. The company’s shares closed last Monday at $8.92.
According to TipRanks.com, Wittes is a 4-star analyst with an average return of 16.3% and a 63.2% success rate. Wittes covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Alphatec Holdings, and Globus Medical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Brainsway with a $13.95 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $11.04 and a one-year low of $5.52. Currently, Brainsway has an average volume of 86.07K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Brainsway Ltd. engages in the research, development and marketing of medical device for non-invasive treatment of the brain disorders. Its technology enables handling of a wide range of indications through the TMS Deep system developed by the company. Brainsway operates through the following segments: Major depression and Obsessive Compulsive Disorder (OCD). The company was founded by Avner Hagai, Yiftach Roth, Abraham Zangen, and David Zacut on November 7, 2006 and is headquartered in Jerusalem, Israel.
